AR070071A1 - Derivados de n- fenil - imidazo (1,2-alfa) piridin -2- carboxamidas, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de n- fenil - imidazo (1,2-alfa) piridin -2- carboxamidas, su preparacion y su aplicacion en terapeutica

Info

Publication number
AR070071A1
AR070071A1 ARP080105776A ARP080105776A AR070071A1 AR 070071 A1 AR070071 A1 AR 070071A1 AR P080105776 A ARP080105776 A AR P080105776A AR P080105776 A ARP080105776 A AR P080105776A AR 070071 A1 AR070071 A1 AR 070071A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
phenyl
imidazo
hydrogen atom
Prior art date
Application number
ARP080105776A
Other languages
English (en)
Inventor
Jean-Francois Peyronel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR070071A1 publication Critical patent/AR070071A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Composicion farmacéutica y usos para tratar enfermedades que involucran los receptores nucleares Nurr-1. Reivindicacion 1: Compuestos de formula (1), en la que: X representa un grupo fenilo sustituido con un ciano, un alcoxi C1-6carbonilo, un alcoxi C1-6 sustituido con uno o varios halogenos o alquilo C1-6 sustituido con uno o varios halogenos, estando el fenilo opcionalmente sustituido una segunda vez con un halogeno; R1 representa un átomo de hidrogeno, un halogeno, un grupo alcoxi C1-6, alquilo C1-6, un grupo NRaRb; pudiendo estar los grupos alquilo y alcoxi sustituidos opcionalmente con uno o varios halogeno, hidroxi, amino o grupo alcoxi C1-6, R2 representa uno de los siguientes grupos: un átomo de hidrogeno, un grupo alquilo C1-6 opcionalmente sustituido con uno o varios grupos elegidos independientemente uno de otros entre un hidroxi, halogeno, amino, un grupo NRaRb, un grupo alcoxi C1-6, un grupo fenilo, un grupo alcoxi C1-6 opcionalmente sustituido con uno o varios grupos elegidos independientemente uno de otros entre hidroxi, halogeno, amino, grupo NRaRb, un grupo alquenilo C2-6, alquinilo C2-6; -CO-R5, -CO-NR6R7, -CO-O-R8, -NR9-CO-R10, -NR11R12, -N=CH-NRaRb, un átomo de halogeno, un grupo ciano, nitro, hidroxiiminoalquilo, alcoxiiminoalquilo, un grupo alquiltio C1-6, alquil C1-6sulfinilo, alquil C1-6sulfonilo, (alquil C1-6)3sililetinilo, -SO2-NR9R10, fenilo opcionalmente sustituido con uno o varios grupos elegidos independientemente uno de otros entre los átomos o grupos siguientes: halogeno, alcoxi C1-6, ciano, NRaRb, -CO-R5, -CO-NR6R7, -CO-O-R8, un grupo alquilo C1-6 opcionalmente sustituido con uno o varios hidroxi o NRaRb, R3 representa un átomo de hidrogeno, un grupo alquilo C1-6, alcoxi C1-6 o un átomo de halogeno, R4 representa un átomo de hidrogeno, un grupo alquilo C1-4, alcoxi C1-4 o un átomo de fluor, R5 representa un átomo de hidrogeno, un grupo fenilo o alquilo C1-6, R6 y R7, idénticos o diferentes, representan un átomo de hidrogeno o un grupo alquilo C1-6 o forman con el átomo de nitrogeno un ciclo de 4 a 7 eslabones que incluye opcionalmente otro heteroátomo elegido entre N, O o S; R8 representa un grupo alquilo C1-6, R9 y R10, idénticos o diferentes, representan un átomo de hidrogeno o un grupo alquilo C1-6; R11 y R12 idénticos o diferentes, representan un átomo de hidrogeno o un grupo alquilo C1-6 o forman con el átomo de nitrogeno un ciclo de 4 a 7 eslabones que incluye opcionalmente otro heteroátomo elegido entre N, O o S; Ra y Rb representan, independientemente uno de otros, un átomo de hidrogeno, un grupo alquilo C1-6 o forman con el átomo de nitrogeno un ciclo de 4 a 7 eslabones, con la excepcion de los compuestos en los que R1 representa un grupo metilo o R2 representa un átomo de cloro o R3 representa un grupo metilo, en el estado de base o de sal de adicion de un ácido, con la excepcion de los compuestos: N-(3-cloro-4-cianofenil)-imidazo[1,2-a}piridina-2-carboxamida, 3-({[imidazo[1,2-a]piridina-2-il]carbonil}amino)benzoato de metilo, 2-({[imidazo[1,2-a]piridina-2-il]carbonil}amino)benzoato de metilo, N-[2-(difluorometoxi)fenil]-imidazo[1,2-a]piridina-2-carboxamida, N-[3-(trifluorometoxi)fenil]-6-(dimetilamino)imidazo[1,2-a]piridina-2-carboxamida, N-[3-(difluorometoxi)fenil]-6-(dimetilamino)imidazo{1,2-a]piridina-2-carboxamida, y N-[3-(trifluorometil)fenil]-6-(dimetilamino)imidazo[1,2-a]piridina-2-carboxamida.
ARP080105776A 2008-01-02 2008-12-30 Derivados de n- fenil - imidazo (1,2-alfa) piridin -2- carboxamidas, su preparacion y su aplicacion en terapeutica AR070071A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0800002A FR2925900B1 (fr) 2008-01-02 2008-01-02 DERIVES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Publications (1)

Publication Number Publication Date
AR070071A1 true AR070071A1 (es) 2010-03-10

Family

ID=39691313

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105776A AR070071A1 (es) 2008-01-02 2008-12-30 Derivados de n- fenil - imidazo (1,2-alfa) piridin -2- carboxamidas, su preparacion y su aplicacion en terapeutica

Country Status (21)

Country Link
US (1) US20100317685A1 (es)
EP (1) EP2225241B1 (es)
JP (1) JP2011508758A (es)
KR (1) KR20100099245A (es)
CN (1) CN101910176A (es)
AR (1) AR070071A1 (es)
AT (1) ATE524468T1 (es)
AU (1) AU2008351926A1 (es)
BR (1) BRPI0821674A2 (es)
CA (1) CA2710943A1 (es)
CL (1) CL2008003926A1 (es)
CO (1) CO6321243A2 (es)
EA (1) EA201070816A1 (es)
FR (1) FR2925900B1 (es)
IL (1) IL206668A0 (es)
MA (1) MA32060B1 (es)
MX (1) MX2010007348A (es)
TW (1) TW200942539A (es)
UY (1) UY31586A1 (es)
WO (1) WO2009106748A2 (es)
ZA (1) ZA201004641B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903108B1 (fr) * 2006-07-03 2008-08-29 Sanofi Aventis Sa Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique.
FR2925906B1 (fr) * 2008-01-02 2010-08-20 Sanofi Aventis COMPOSES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2950344B1 (fr) * 2009-09-18 2011-11-25 Sanofi Aventis Derives de 5-phenyl-pyrazolopyridine, leur preparation et leur aplication en therapeutique.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638161B1 (fr) * 1988-10-24 1991-01-11 Centre Nat Rech Scient Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US20050171172A1 (en) * 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
DE602005013819D1 (de) * 2004-12-22 2009-05-20 Astrazeneca Ab Pyridincarbonsäureamidderivate zur verwendung als antikrebsmittel
FR2903107B1 (fr) * 2006-07-03 2008-08-22 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2903108B1 (fr) * 2006-07-03 2008-08-29 Sanofi Aventis Sa Utilisation de derives d'imidazo[1,2-a] pyridine-2-carboxamides en therapeutique.
FR2925906B1 (fr) * 2008-01-02 2010-08-20 Sanofi Aventis COMPOSES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Also Published As

Publication number Publication date
MA32060B1 (fr) 2011-02-01
WO2009106748A2 (fr) 2009-09-03
MX2010007348A (es) 2010-08-18
TW200942539A (en) 2009-10-16
JP2011508758A (ja) 2011-03-17
EP2225241A2 (fr) 2010-09-08
EP2225241B1 (fr) 2011-09-14
CO6321243A2 (es) 2011-09-20
FR2925900A1 (fr) 2009-07-03
ZA201004641B (en) 2011-09-28
AU2008351926A1 (en) 2009-09-03
EA201070816A1 (ru) 2010-12-30
KR20100099245A (ko) 2010-09-10
WO2009106748A3 (fr) 2009-12-30
UY31586A1 (es) 2009-08-03
CA2710943A1 (fr) 2009-09-03
IL206668A0 (en) 2010-12-30
BRPI0821674A2 (pt) 2015-06-16
CL2008003926A1 (es) 2010-02-12
FR2925900B1 (fr) 2011-03-04
ATE524468T1 (de) 2011-09-15
US20100317685A1 (en) 2010-12-16
CN101910176A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
PE20091321A1 (es) Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion en terapeutica
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
UY30183A1 (es) Derivados de quinolina
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
AR050617A1 (es) Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas
PE20081549A1 (es) Derivados de n-(amino-heteroaril)-1h-pirrolopiridin-2-carboxamida y su preparacion
AR085283A1 (es) Antagonistas de hepcidina a base de sulfonaminoquinolina
UY29609A1 (es) Derivados de benzamidina y usos relacionados de los mismos
PE20161343A1 (es) Benzamidas sustituidas para el tratamiento de artropodos
PE20130339A1 (es) Compuestos heterociclicos y sus usos
ECSP12011867A (es) Derivados bencimidazol-imidazol
DK1940351T3 (da) Formulering af småmolekylære lægemidler med langvarig frigørelse
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
AR050698A1 (es) Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto
AR063643A1 (es) Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas
AR047466A1 (es) Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles.
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
AR077892A1 (es) Quinolinas antagonistas de la hepcidina
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5
PE20091092A1 (es) Compuestos heterociclicos como inhibidores de la via hedgehog
MX2010007351A (es) Derivados de imidazo[1,2-a]piridina-2-carboxamidas, su preparacion y su aplicacion en terapeutica.
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.

Legal Events

Date Code Title Description
FB Suspension of granting procedure